Vergelijking
Pasireotid vs. Bremelanotide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
396091-73-9
189691-06-3
Molecuulmassa
1047.21 g/mol
1025.18 g/mol
Halfwaardetijd
geen gegevens
2.7 h
Sequentie
geen gegevens
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHWerkingsmechanisme
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
1
5
waarvan bij mensen
1
5
Geregistreerde effecten
2
3
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
2
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Pasireotid and Bremelanotide?
- Pasireotid is classified as "Onderzoek (overig)", while Bremelanotide is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Pasireotid or Bremelanotide?
- The highest available evidence level is "Humane RCT" for Pasireotid and "Humane RCT" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Pasireotid and Bremelanotide in Germany and the United States?
- Duitsland: Pasireotid — Op recept, Bremelanotide — Niet goedgekeurd. Verenigde Staten: Pasireotid — Op recept, Bremelanotide — Op recept. These are factual summaries with source and review date on the individual pages.